Skip to main content

Sequenom Launches Public Offering to Raise $54M


Sequenom has launched a public offering of 13 million shares, from which it expects to raise $54 million.

The company plans to use the proceeds for "general corporate purposes, including research and development expenses, capital expenditures, working capital, and general administrative expenses."

In documents filed with the US Securities and Exchange Commission, Sequenom said that it has sufficient capital to operate through early 2013, but that it would need to raise additional funds to support the commercialization of its MaterniT21 test, which it launched in October (CSN 10/19/2011).

Specifically, it said that it would need to increase its direct sales force, enter into collaborative relationships with third parties to expand sales and marketing channels, educate clinicians and other healthcare professionals about MaterniT21, expand its clinical diagnostic laboratory and hospital outreach laboratory customers, and establish and expand its reimbursement arrangements.

As of Dec. 31, 2011, the company had $84.2 million in cash, cash equivalents, and marketable securities.

The public can purchase stock at $4.15 per share, and underwriters can purchase stock at $3.92 per share. Additionally, underwriters have a 30-day option to purchase an aggregate of 1,950,000 shares of common stock to cover over-allotments.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.